Results 1 to 10 of about 1,766 (97)

Vaccine response in people with multiple sclerosis treated with fumarates [PDF]

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023
People with multiple sclerosis (pwMS) have an increased risk of infection. As disease-modifying therapies (DMTs) and other treatments may interact with the immune system, there may be concerns about vaccine efficacy and safety. Therefore, it is important
Matthew A Tremblay, Sandra Vukusic, Ivan Božin   +2 more
exaly   +3 more sources

Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims database [PDF]

Journal of Comparative Effectiveness Research
Aim: Anti-CD20 monoclonal antibodies and fumarates are common multiple sclerosis (MS) diseasemodifying therapies (DMTs). Data on switching from anti-CD20s to other DMTs are limited.
Brandon P Moss, Nicholas Belviso, Jason P Mendoza   +2 more
exaly   +3 more sources

Transition from anti-CD20 therapies to fumarates as a treatment strategy: A multicenter, retrospective observational experience [PDF]

Multiple Sclerosis Journal - Experimental, Translational and Clinical
We present real-world data on patients switching from anti-CD20s to fumarates for various motivations in this retrospective observational study of 43 patients from three multiple sclerosis centers.
Brandi L Vollmer, Tammy Hoyt, Timothy W West, Josef Gutman, Monica Benitez, Evan L Riddle, James B Lewin, Jason P Mendoza, Enrique Alvarez   +8 more
doaj   +2 more sources

Comparative Effectiveness of Fumarates Versus Sphingosine-1-Phosphate Receptor Modulators in Black Patients with Multiple Sclerosis [PDF]

Neurology and Therapy
Introduction Multiple sclerosis (MS) is a heterogeneous disease that disproportionately impacts Black people with MS (PwMS), who experience more severe disease and higher relapse rates compared with non-Black populations.
Sophia Woodson, Edward J. Gettings, Chu-Yueh Guo, Sylvia Klineova, Jong-Mi Lee, Rebecca S. Romero, Aljoeson Walker, Nicholas Belviso, Sai L. Shankar, Jason P. Mendoza, Boyang Bian, James B. Lewin, Kinyee Fong   +12 more
doaj   +2 more sources

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA [PDF]

Neurology and Therapy
Introduction Multiple sclerosis (MS) is a heterogeneous disease affecting a diverse population. Compared with white people with MS (PwMS), Black PwMS have more severe disease and higher incidence of MS, whereas Hispanic PwMS experience earlier onset ...
Sophia Woodson, Edward J. Gettings, Chu-Yueh Guo, Sylvia Klineova, Jong-Mi Lee, Rebecca S. Romero, Aljoeson Walker, Kinyee Fong, Jason P. Mendoza, Nicholas Belviso, Boyang Bian, James B. Lewin, Sai L. Shankar   +12 more
doaj   +2 more sources

Fumarate-based drugs protect against neuroinflammation via upregulation of anti-ferroptotic pathways [PDF]

Journal of Neuroinflammation
Ferroptosis is defined as iron dependent non-apoptotic cell death. It is based on peroxidation of polyunsaturated phospholipids and subsequent membrane rupture.
Katinka Fischer, Leonie Thewes, Tim Prozorovski, Mary Bayer, Michael Dietrich, Torsten Lowin, Philipp Albrecht, Hans-Peter Hartung, Sven G. Meuth, Orhan Aktas, Carsten Berndt   +10 more
doaj   +2 more sources

Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses [PDF]

Frontiers in Immunology
BackgroundThere is a greater risk of complications from severe COVID-19 in immunocompromised patients with multiple sclerosis (pwMS) treated with certain disease-modifying therapies (DMTs), as well as a diminished vaccine response.MethodsIn this ...
Ryan Curtin, Ryan Curtin, Ryan Curtin, Yogambigai Velmurugu, Yogambigai Velmurugu, Yogambigai Velmurugu, Fatoumatta Dibba, Fatoumatta Dibba, Fatoumatta Dibba, Yuan Hao, Samantha Nyovanie, Samantha Nyovanie, Samantha Nyovanie, Andrea Lopez, Andrea Lopez, David Mieles, David Mieles, Courtney Ng, Courtney Ng, Courtney Ng, Katherine Perdomo, Nicole Scott, James B. Lewin, Robin L. Avila, Jen Smrtka, Yury Patskovsky, Yury Patskovsky, Yury Patskovsky, Jonathan Howard, Jonathan Howard, Gregg J. Silverman, Michelle Krogsgaard, Michelle Krogsgaard, Michelle Krogsgaard   +33 more
doaj   +2 more sources

Polymorphism and Multi-Component Crystal Formation of GABA and Gabapentin [PDF]

Pharmaceutics, 2023
This study exploits the polymorphism and multi-component crystal formation of γ-amino butanoic acid (GABA) and its pharmaceutically active derivative, gabapentin.
Daniel Komisarek, Fulya Demirbas, Takin Haj Hassani Sohi, Klaus Merz, Carsten Schauerte, Vera Vasylyeva   +5 more
doaj   +2 more sources

Pharmacomicrobiomics in Psoriasis: Microbiome–Drug Interactions Across Systemic Treatments [PDF]

Life
Psoriasis is a chronic immune-mediated skin disease with highly variable responses to systemic therapies. Emerging evidence highlights the microbiome as a potential modulator of drug efficacy and toxicity. Gut bacteria can enzymatically metabolize drugs,
Umberto Santaniello, Luca Mastorino, Valentina Pala, Francois Rosset, Orsola Crespi, Pietro Quaglino, Simone Ribero   +6 more
doaj   +2 more sources

How should we do in the selection and follow-up of systemic conventional treatments in psoriasis? [PDF]

Exploration of Musculoskeletal Diseases, 2023
There is an increasing need for appropriate effective treatment and long-term disease control in patients with psoriasis because of the decreased quality of life, increased physicosocial deficits and associated co-morbidities.
Sevgi Akarsu
doaj   +1 more source